Theravance Biopharma (TBPH) EBT Margin (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly EBT Margin of 36.56% for Q1 2026, up 5532.0% year-over-year from 0.65% in Q1 2025, and down 132.13% quarter-over-quarter from 113.77% in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) EBT Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported EBT Margin for 14 consecutive years, with 36.56% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 5532.0% year-over-year to 36.56%; the TTM figure through Mar 2026 stood at 105.72% (up 17980.0% YoY), while the FY2025 annual figure was 1445.2%, up 151450.0% from the prior year.
- EBT Margin retreated to 36.56% in Q1 2026 per TBPH's latest filing, from 113.77% in the prior quarter.
- Across five years, EBT Margin topped out at 279.47% in Q2 2025 and bottomed at 301.11% in Q1 2022.
- Historically, EBT Margin has averaged 68.51% across 5 years, with a median of 71.72% in 2024.
- On a YoY basis, EBT Margin climbed as much as 38623 bps in 2025 and fell as far as 2015 bps in 2025.
- Theravance Biopharma's EBT Margin stood at 97.34% in 2022, then soared by 71 bps to 28.56% in 2023, then sank by 67 bps to 47.66% in 2024, then soared by 339 bps to 113.77% in 2025, then slumped by 132 bps to 36.56% in 2026.
- Business Quant data shows TBPH's EBT Margin at 36.56% in Q1 2026, 113.77% in Q4 2025, and 14.45% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -23.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.11% |
| Mar 31, 2026 | -36.56% |
| Dec 31, 2025 | 159.22% |
| Sep 30, 2025 | -14.45% |
| Jun 30, 2025 | 279.47% |
| Mar 31, 2025 | -91.88% |
| Dec 31, 2024 | -58.40% |
| Sep 30, 2024 | -59.59% |
| Jun 30, 2024 | -106.77% |
| Mar 31, 2024 | -71.72% |
| Dec 31, 2023 | -28.56% |
| Sep 30, 2023 | -48.32% |
| Jun 30, 2023 | -103.19% |
| Mar 31, 2023 | -215.83% |
| Dec 31, 2022 | -97.34% |
| Sep 30, 2022 | -128.69% |
| Jun 30, 2022 | -206.32% |
| Mar 31, 2022 | -301.11% |
| Dec 31, 2021 | -387.84% |
| Sep 30, 2021 | -423.81% |